Skip to main content
Fig. 2 | Cancer Nanotechnology

Fig. 2

From: Cabazitaxel-loaded human serum albumin nanoparticles combined with TGFβ-1 siRNA lipid nanoparticles for the treatment of paclitaxel-resistant non-small cell lung cancer

Fig. 2

Preparation and Characterization of CTX-HSA-NPs. A Particle sizes of CTX-HSA-NPs (6∶1), CTX-HSA-NPs (8∶1) and CTX-HSA-NPs (10∶1). B The TEM and SEM images of CTX-HSA-NPs (6∶1), CTX-HSA-NPs (8∶1) and CTX-HSA-NPs (10∶1). C Sample of CTX-Tween; Samples of CTX-HSA-NPs (6∶1), CTX-HSA-NPs (8∶1) and CTX-HSA-NPs (10∶1) lyophilized powder (C 2,3,4); Sample of CTX-HSA-NPs (6∶1), CTX-HSA-NPs (8∶1) and CTX-HSA-NPs (10∶1) liquid preparations (C 5,6,7). D In vitro release curves of CTX-HSA-NPs (6∶1), CTX-HSA-NPs (8∶1) and CTX-HSA-NPs (10∶1). E: The stability of CTX-HSA-NPs lyophilized powder at 25 °C for 24 days after dissolving in normal saline

Back to article page

Cancer Nanotechnology

ISSN: 1868-6966

Contact us